^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Burkitt Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    MabThera in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with...Burkitt lymphoma (BL)…
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Burkitt Lymphoma: Induction therapy <60 y…cytarabine + rituximab (regimen includes intrathecal therapy)
    Secondary therapy:
    cytarabine